Literature DB >> 17414637

Reirradiation in squamous cell head and neck cancer: recent developments and future directions.

Johannes A Langendijk1, Jean Bourhis.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to highlight the most important developments in the management of recurrent or second primary head and neck carcinoma in previously irradiated areas by reirradiation that have been published in the medical literature in the past year. RECENT
FINDINGS: Recent research indicates that long-term survival can be achieved in a proportion of patients using more advanced chemo-reirradiation protocols in the primary as well as in postoperative reirradiation setting. Despite the promising results with regard to locoregional tumour control and survival, treatment-related acute and late morbidity remains of major concern.
SUMMARY: As an increasing number of patients currently receive more effective initial treatment regimens, recurrent and second primary tumours in previously irradiated areas nowadays may represent a more radio-resistant population than reported in previous studies. Therefore, full-dose chemo-reirradiation should only be applied in well selected cases.

Entities:  

Mesh:

Year:  2007        PMID: 17414637     DOI: 10.1097/CCO.0b013e3280f00ff8

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  7 in total

1.  Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Authors:  L Vormittag; C Lemaire; D Radonjic; G Kornek; E Selzer
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

Review 2.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

3.  Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol.

Authors:  Bernhard Berger; Claus Belka; Martin Weinmann; Michael Bamberg; Wilfried Budach; Thomas Hehr
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

4.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

5.  Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.

Authors:  Panagiotis Balermpas; Markus Hambek; Oliver Seitz; Claus Rödel; Christian Weiss
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

6.  Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study.

Authors:  Keiichi Jingu; Yuzuru Niibe; Hideomi Yamashita; Kuniaki Katsui; Toshihiko Matsumoto; Tomohiro Nishina; Atsuro Terahara
Journal:  Radiat Oncol       Date:  2017-09-05       Impact factor: 3.481

7.  RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison.

Authors:  Dirk Van Gestel; Corine van Vliet-Vroegindeweij; Frank Van den Heuvel; Wouter Crijns; Ann Coelmont; Bie De Ost; Andrea Holt; Emmy Lamers; Yasmyne Geussens; Sandra Nuyts; Danielle Van den Weyngaert; Tim Van den Wyngaert; Jan B Vermorken; Vincent Gregoire
Journal:  Radiat Oncol       Date:  2013-02-20       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.